Brain Cancer Immunotherapy in China: Nanoparticle Platform Shows Promise Against Glioblastoma
For Patients Seeking Brain Cancer Treatment: A New Research Direction
For patients and families searching for brain cancer immunotherapy in China, the challenge of treating glioblastoma (GBM) — the most aggressive form of brain cancer — is well known. Standard treatments often fall short because the blood-brain barrier blocks most drugs, and the tumor creates an environment that suppresses the body’s own immune response. A new study from Southeast University in Nanjing, published in Nature Communications, describes an experimental nanoparticle platform designed to overcome both of these obstacles simultaneously.
What the Southeast University Team Developed
Researchers led by Professor Xie Jinbing and Associate Researcher Zhu Yini at Southeast University’s School of Medicine have engineered a tumor-responsive lipid nanoparticle system called PL@mBiME. Their work, published on June 10, 2026, addresses two core problems in glioblastoma treatment: getting therapeutic molecules across the blood-brain barrier, and reprogramming the tumor’s immune microenvironment from suppressive to active.
The platform carries messenger RNA (mRNA) that instructs cells to produce a bispecific macrophage engager called BiME. This engager has two binding ends — one targets the ErbB2/HER2 protein on glioblastoma cells, and the other targets the CD206 receptor on tumor-associated macrophages (TAMs). By physically bridging cancer cells and macrophages, BiME encourages macrophages to recognize, engulf, and destroy tumor cells while also improving antigen presentation to other immune cells.
How the Nanoparticle Overcomes the Blood-Brain Barrier
Getting drugs into the brain is notoriously difficult. The team modified the nanoparticle surface with a peptide called Angiopep-2, which binds to receptors on brain blood vessel cells and facilitates transport across the barrier. Additionally, they incorporated an acid-responsive lipid component that causes the nanoparticle to undergo a charge reversal in the mildly acidic tumor microenvironment. This change enhances cellular uptake and helps the cargo escape from endosomes inside cells, ensuring the mRNA reaches the cytoplasm where it can be translated into functional protein.
The platform also co-delivers a PD-L1 antibody, a type of immune checkpoint inhibitor. While the BiME protein activates macrophages, the PD-L1 antibody helps remove the brakes on T cells, allowing CD8+ T cells to infiltrate the tumor and mount a coordinated attack. This dual mechanism links innate immunity (macrophages) with adaptive immunity (T cells).
What the Experiments Showed
In mouse models of orthotopic glioblastoma — where tumors grow in the brain as they do in humans — the PL@mBiME platform demonstrated several significant effects:
- Effective brain delivery: The nanoparticles successfully crossed the blood-brain barrier and accumulated in brain tumor tissue, enabling efficient mRNA delivery and BiME expression in vivo.
- Macrophage reprogramming: The expressed BiME protein promoted a shift from immunosuppressive M2-type macrophages to pro-inflammatory, tumor-fighting M1-type macrophages, enhancing their ability to engulf tumor cells.
- Tumor suppression and survival: In multiple GBM mouse models, the treatment significantly inhibited tumor growth and extended survival time. In some animals, tumors were completely eliminated.
- Immune memory: Further investigation revealed that the treatment induced durable anti-tumor immune memory. When surviving mice were re-challenged with tumor cells, they showed clear protection, suggesting a potential to reduce recurrence risk.
The study’s first author is doctoral candidate Zhang Haoge from Southeast University’s School of Medicine. The research was supported by the National Natural Science Foundation of China and the National Key Research and Development Program.
Source: 东南大学医学院 | Original paper: Nature Communications
What This Means for Patients
While this nanoparticle platform remains in preclinical development and has not yet entered human trials, the findings reflect the growing sophistication of brain cancer immunotherapy research in China. For international patients evaluating options for glioblastoma, this study underscores that Chinese research institutions are actively working on the very barriers — blood-brain barrier penetration and tumor immune suppression — that make this disease so difficult to treat. As these technologies progress toward clinical application, they may one day expand the range of treatments available at centers pursuing world-class medical care in China. For now, patients should discuss all experimental and approved treatment options with their oncology team, and can explore current clinical trial availability through resources like ToChinaMed.
Reviewed by ToChinaMed. Published: 2026-06-11. This article is based on publicly available medical news and is not a substitute for professional medical advice.
ToChinaMed helps international patients find reliable medical treatment in China.